Meeting
2017 ASCO Annual Meeting
A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.
Authors
Yoon-Koo Kang
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Yoon-Koo Kang , Narikazu Boku , Won Ki Kang , Harry H. Yoon , Stefano Cascinu , Salah-Eddin Al-Batran , Scott Houston , Cheol Hee Park , Arlo N. McGinn , Ian Chau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03042611
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS4138)
DOI
10.1200/JCO.2017.35.15_suppl.TPS4138
Abstract #
TPS4138
Poster Bd #
126b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
First Author: Huaying Wang
Poster
2021 Gastrointestinal Cancers Symposium
Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).
First Author: Yasuyuki Kawamoto
Poster
2019 ASCO Annual Meeting
Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in patients with advanced triple-negative breast cancer.
First Author: Jieqiong Liu
Poster
2019 Gastrointestinal Cancers Symposium
HGCSG 1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer.
First Author: Atsushi Ishiguro